Restless Legs Syndrome (RLS) is a prevalent neurological disorder characterized by an irresistible urge to move the limbs, typically the legs, often accompanied by uncomfortable sensations. Despite its high prevalence and significant impact on daily life, RLS remains underdiagnosed and frequently misdiagnosed in primary care settings. This article aims to provide a comprehensive guide for primary care physicians on the diagnosis and management of RLS, enhancing early recognition and effective treatment strategies.
Barriers to Accurate RLS Diagnosis
One of the primary challenges in RLS management is underdiagnosis and misdiagnosis. Patients often experience a diagnostic delay of several years, particularly those with childhood-onset RLS. This delay is attributed to several factors, including the diverse ways patients describe their symptoms and the overlap with other conditions.
Studies highlight the significant gap between RLS prevalence and diagnosed cases. A German survey indicated that only 2.3% of the population had a formal RLS diagnosis, with a diagnosed-to-undiagnosed ratio of 1:3 [1]. French research revealed that merely 5.3% of RLS sufferers received a diagnosis, despite over half consulting doctors about their symptoms [2]. The REST primary care study in the USA and Europe found that while nearly 65% of sufferers consulted a physician, only 12.9% received an RLS diagnosis [3]. These findings are echoed in studies from the UK, USA, and Ireland, consistently demonstrating underdiagnosis and mismanagement of RLS in primary care [4, 5, 6].
Common misdiagnoses include skin irritation, arthritis, venous disorders, and malingering in adults. In children, RLS is often mistaken for growing pains or Attention Deficit Hyperactivity Disorder (ADHD). Such misdiagnoses delay appropriate treatment and prolong patient suffering.
Clinical Diagnosis of Restless Legs Syndrome
The diagnosis of RLS is primarily clinical, based on the International Restless Legs Syndrome Study Group (IRLSSG) essential criteria. There is no definitive biological marker; however, diagnostic certainty can be increased by supportive criteria.
Essential Diagnostic Criteria for RLS
A clinical diagnosis requires the presence of all four of the following criteria:
-
Urge to move the legs: This is often accompanied by unpleasant sensations. While primarily in the legs, these sensations can also affect the arms, trunk, and face. Patients struggle to describe these sensations, using terms such as creeping, crawling, itching, burning, tugging, aching, or like an electric current [7, 8]. Some patients may experience the urge to move without pronounced sensory discomfort.
-
Symptoms worsen with rest or inactivity: The urge to move and unpleasant sensations begin or intensify during periods of rest, such as sitting or lying down. Physical immobility and reduced central nervous system activity associated with rest are thought to trigger symptoms [9].
-
Relief with movement: Symptoms are partially or totally relieved by movement. Activities like walking or stretching can alleviate discomfort, but symptoms often return shortly after ceasing movement. The severity of RLS dictates the intensity of movement needed for relief. Counter-stimulation, such as massaging or tapping the legs, can also provide temporary relief.
-
Circadian pattern: Symptoms are worse in the evening or at night, or occur exclusively during these times. Symptoms typically peak around midnight and are least pronounced mid- to late-morning [10, 11]. This circadian rhythm may be linked to the diurnal variation in iron availability and its impact on dopamine synthesis [12].
Supportive clinical criteria that enhance diagnostic confidence include a positive response to levodopa, the presence of periodic limb movements (PLMs), and a family history of RLS [7].
Differential Diagnosis and RLS Mimics
Accurate RLS diagnosis requires awareness of the disorder and its varied presentations. Misdiagnosis is more likely when clinicians lack familiarity with RLS or fail to differentiate it from conditions mimicking its symptoms.
Important RLS mimics include peripheral neuropathy, leg cramps, positional discomfort, akathisia, and anxiety disorders [13]. Furthermore, RLS can coexist with conditions like peripheral neuropathy, lower limb pain from other causes, and Parkinsonism, complicating diagnosis.
Ekbom’s description of “irritable legs” emphasizes that RLS sensations are felt deep within the legs, particularly in the calf or shin, never superficially in the skin [14]. The high comorbidity of RLS in Parkinson’s disease may be related to medication effects or symptom overlap [15, 16].
Table 1: Common Terms Used to Describe RLS Symptoms
| Category | Terms |
|---|---|
| Creeping/Crawling | Creeping, crawling, insects crawling, ants crawling |
| Itching/Burning | Itching, burning, prickling, stinging |
| Tugging/Pulling | Tugging, pulling, drawing, stretching |
| Aching/Painful | Aching, painful, throbbing, cramping |
| Electric/Restless | Electric current, restless, jittery, nervous energy |
| Indescribable | Indescribable, weird, uncomfortable, annoying, pins and needles |
It is crucial to consider these differential diagnoses to avoid mislabeling conditions as RLS and to ensure appropriate management.
Diagnostic Algorithm for Primary Care
To improve RLS diagnosis in primary care, a systematic approach is essential. A diagnostic algorithm incorporating leading symptoms and validated tools can streamline the diagnostic process.
Step 1: Identifying Leading Symptoms
Initial patient assessment should focus on two primary presenting complaints: insomnia or sleep disturbances and unpleasant sensations in the legs. Epidemiological studies and clinical experience indicate these as key indicators [4, 3, 17].
The REST primary care study highlighted sleep-related issues and leg discomfort as the most bothersome symptoms for RLS patients [3]. A general population study reported that over 75% of RLS sufferers experience sleep-related problems [4]. Research by Crochard et al. demonstrated that leg complaints and sleep disturbances are significant diagnostic indicators for RLS in primary care consultations [17].
Step 2: Utilizing the RLS Diagnostic Index (RLS-DI)
If a patient presents with insomnia/sleep problems and leg discomfort, the RLS Diagnostic Index (RLS-DI) is a recommended tool [18]. The RLS-DI is a validated algorithm combining essential and supportive RLS criteria. It involves asking a series of targeted questions, focusing on the urge to move the legs and symptom worsening at rest.
Patients answering “yes” to three or more RLS-DI questions should be further evaluated for associated and supportive features, such as family history of RLS, positive response to dopaminergic therapy, and exclusion of RLS mimics (Table 3 from original article – not included here for brevity). A positive response to one or more supportive features strengthens the likelihood of RLS diagnosis.
General Treatment Considerations for RLS
RLS is typically a chronic condition requiring long-term management. Primary RLS tends to progress over time, especially in early-onset cases [19]. Late-onset RLS may exhibit a more rapid symptom progression [20]. While symptom remission is possible, primary RLS often necessitates lifelong treatment. Patients should be informed about the chronic nature of RLS and potential long-term treatment needs, including possible side effects.
Secondary RLS, in contrast, may remit upon resolution of the underlying cause, such as pregnancy, iron deficiency, or renal insufficiency [21, 22, 23]. However, the distinction between primary and secondary RLS can be blurred, as iron deficiency is frequently implicated in primary RLS and may require ongoing management.
RLS treatment is symptomatic, aiming to improve patient quality of life. Close collaboration between physician and patient is crucial to tailor treatment to individual needs and symptom fluctuations. Many RLS medications have short half-lives and are best administered shortly before symptom onset, typically in the evening. Rotigotine, a 24-hour transdermal patch, offers a longer-acting option, simplifying administration [24].
Exacerbating Factors and Medication Review
Prior to initiating pharmacological treatment, it is important to review potential RLS exacerbators. Many patients will have already explored non-pharmacological measures like lifestyle adjustments and home remedies. Medications known to worsen RLS symptoms should be reconsidered or avoided. These include antihistamines, dopamine antagonists, anti-nausea drugs, antidepressants (particularly serotonergic reuptake inhibitors), neuroleptics, beta-blockers, some anticonvulsants, and lithium [25].
Table 2: Drugs That May Exacerbate RLS
| Category | Examples |
|---|---|
| Antihistamines | Diphenhydramine, Chlorpheniramine |
| Dopamine Antagonists | Metoclopramide, Prochlorperazine |
| Anti-Nausea Medications | Promethazine |
| Antidepressants (SSRIs) | Fluoxetine, Sertraline, Paroxetine |
| Neuroleptics | Haloperidol, Risperidone |
| Beta-Blockers | Propranolol, Metoprolol |
| Anticonvulsants (certain) | Phenytoin |
| Lithium | Lithium Carbonate |
Minimizing Drug Dosages
RLS medication dosages should be kept to the minimum effective level, never exceeding the maximum recommended regulatory dose. Dopaminergic agents, for instance, require significantly lower doses for RLS than for Parkinson’s disease. Dividing doses should be avoided if it necessitates increasing the total daily dosage. However, in some patients, a single daily dose may be insufficient, requiring careful monitoring to maintain the lowest effective 24-hour dose.
Sufficient treatment duration is essential before switching medications. Dosage increases should be approached cautiously and gradually to avoid augmentation, a serious treatment complication.
When to Initiate RLS Treatment
RLS treatment should be initiated only when symptoms are clinically significant, meaning they negatively impact a patient’s quality of life, daytime functioning, social interactions, or sleep. To assess RLS severity and monitor treatment effectiveness, a simple sleep diary is recommended for 7-14 days.
How to Treat RLS in Primary Care
RLS treatment strategies are categorized based on symptom frequency and severity: intermittent, daily, and refractory RLS.
Treatment Categories and Drug Choices
a) Intermittent RLS: For clinically significant intermittent RLS (symptoms not frequent enough for daily treatment), off-label intermittent use of levodopa or pramipexole can be considered. Other off-label options include low-potency opioids or hypnotics like clonazepam if sleep disturbance is the primary concern.
b) Daily RLS: Daily treatment is necessary for moderate to severe RLS impacting daily life. Dopamine agonists (pramipexole, ropinirole, rotigotine) are first-line choices [26]. Rotigotine is preferred for patients with both nighttime and daytime symptoms due to its longer duration of action [24]. Second-line treatments include opioid-like drugs (tramadol, tilidine, codeine), but long-term use carries addiction risks [26]. Alpha-2-delta ligands (pregabalin, gabapentin, gabapentin enacarbil) are promising alternatives, especially for painful RLS, pending further long-term efficacy data [27, 28].
c) Refractory RLS: Refractory RLS, defined as daily RLS unresponsive to two drug classes (dopaminergic and non-dopaminergic) at adequate doses and duration, requires specialist referral. Primary care management is not recommended for refractory RLS.
d) Primary vs. Secondary RLS: For primary RLS, intermittent or continuous treatment strategies apply. For secondary RLS, addressing underlying causes is crucial. Iron deficiency is frequently associated with secondary RLS and RLS severity. Hemoglobin, transferrin saturation, and serum ferritin should be evaluated in all RLS patients. Oral iron supplementation is recommended when serum ferritin levels are low (<75 μg/L). Intravenous iron may be considered in some cases. Alpha-2 delta agonists (pregabalin, gabapentin) may be beneficial for painful RLS or RLS associated with polyneuropathy. Pramipexole has also shown efficacy in managing pain in RLS patients [29]. For RLS during pregnancy and breastfeeding, iron and folic acid are the recommended treatments. Elderly patients (>75 years) and children with RLS should be referred to specialists.
e) Daytime Symptoms: For RLS with daytime symptoms (occurring in over 40% of cases), rotigotine is recommended due to its 24-hour therapeutic plasma levels [3]. Extended-release dopamine agonists are not yet approved for RLS.
Duration of Treatment and Follow-Up
Currently, data on optimal RLS treatment duration are limited. Treatment cessation should be considered in the following situations: patient request, resolution of underlying causes in secondary RLS (e.g., post-renal transplant), or periodic treatment breaks (annually for a few days, if feasible) to assess spontaneous symptom fluctuations. However, treatment breaks may not be suitable for severely affected patients.
Regular follow-up is crucial. Primary care physicians should review RLS patients every six to twelve months. Symptom diaries are recommended for monitoring treatment efficacy, identifying non-responders, and detecting augmentation. Severity rating scales, while used in clinical trials, are not essential for routine treatment initiation in primary care.
Treatment Complications and Specialist Referral
When to Refer to a Specialist
Referral to a sleep specialist or neurologist is recommended if treatment in primary care is unsuccessful. Unsuccessful treatment is defined by:
- Insufficient initial response despite adequate dose and duration.
- Loss of treatment efficacy over time, even with dose increases.
- Intolerable side effects.
- Reaching maximum recommended dosage without symptom control.
- Development of augmentation.
- Children with RLS should generally be referred to specialists.
Augmentation
Augmentation is a significant complication of long-term dopaminergic RLS treatment. It involves a paradoxical worsening of RLS symptoms, including earlier symptom onset, increased symptom intensity at rest, and symptom spread to other body parts. Preventing augmentation involves using the lowest effective dose of dopaminergic medication, adhering to recommended dosage limits, and considering longer-acting agents.
If augmentation is suspected, switching from a dopaminergic agent to a longer-acting dopamine agonist or a non-dopaminergic drug is advised [30]. In levodopa-induced augmentation, switching to a dopamine agonist is the initial step. If these strategies fail, specialist referral is necessary.
Suspecting Augmentation
Augmentation should be suspected when:
- Sustained worsening of symptoms despite ongoing treatment.
- Increased symptom severity following a dose increase, particularly if dose reduction improves symptoms.
- Earlier onset of symptoms in the afternoon or evening.
- Spread of symptoms to previously unaffected body parts.
- Shorter time to symptom onset during daytime rest.
By adhering to these guidelines, primary care physicians can enhance their ability to diagnose and manage RLS effectively, improving patient outcomes and quality of life.
References
[List of references from the original article, formatted as in the original]
[1] Happe S, Vennemann M, Evers S, Berger K: Treatment wish of individuals with known and unknown restless legs syndrome in the community. J Neurol. 2008, 255 (9): 1365-1371. 10.1007/s00415-008-0922-7.
[2] Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A: Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology. 2005, 65 (2): 239-246. 10.1212/01.wnl.0000168910.48309.4a.
[3] Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L: Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep medicine. 2004, 5 (3): 237-246. 10.1016/j.sleep.2004.03.006.
[4] Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L: Restless legs syndrome prevalence and impact: REST general population study. Archives of internal medicine. 2005, 165 (11): 1286-1292. 10.1001/archinte.165.11.1286.
[5] O’Keeffe ST, Egan D, Myers A, Redmond S: The frequency and impact of restless legs syndrome in primary care. Irish medical journal. 2007, 100 (7): 539-542.
[6] Van De Vijver DA, Walley T, Petri H: Epidemiology of restless legs syndrome as diagnosed in UK primary care. Sleep Med. 2004, 5 (5): 435-440. 10.1016/j.sleep.2004.07.003.
[7] Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003, 4 (2): 101-119. 10.1016/S1389-9457(03)00010-8.
[8] National Heart LaBIWGoRLS: Restless Legs Syndrome: Detection and Management in Primary Care. Am Fam Physician. 2000, 62 (108): 114-
[9] Montplaisir J, Lapierre O, Lavigne G: [The restless leg syndrome: a condition associated with periodic or aperiodic slowing of the EEG]. Neurophysiol Clin. 1994, 24 (2): 131-140. 10.1016/S0987-7053(94)80003-0.
[10] Hening WA, Walters AS, Wagner M, Rosen R, Chen V, Kim S, Shah M, Thai O: Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep. 1999, 22 (7): 901-912.
[11] Trenkwalder C, Hening WA, Walters AS, Campbell SS, Rahman K, Chokroverty S: Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord. 1999, 14 (1): 102-110. 10.1002/1531-8257(199901)14:13.0.CO;2-E.
[12] Earley CJ, Allen RP, Beard JL, Connor JR: Insight into the pathophysiology of restless legs syndrome. J Neurosci Res. 2000, 62 (5): 623-628. 10.1002/1097-4547(20001201)62:53.0.CO;2-H.
[13] Hening WA, Allen RP, Washburn M, Lesage S, Earley CJ: Mimics of the restless legs syndrome can often satisfy the standard diagnostic criteria. Sleep Med. 2004, 27 (Supplement): A297-
[14] Ekbom KA: Asthenia Crurum Paraesthetica. Acta Medica Scandinavica. 1944, 198-
[15] Poewe W, Hogl B: Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease. Neurology. 2004, 63 (8 Suppl 3): S12-16.
[16] Comella CL: Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. Journal of neural transmission. 2006, 349-355. full_text. 70
[17] Crochard A, El Hasnaoui A, Pouchain D, Huas D, Arnulf I, Krieger J, Lainey E, Le Jeunne P, Leger D, Schuck S, et al: Diagnostic indicators of restless legs syndrome in primary care consultations: the DESYR study. Mov Disord. 2007, 22 (6): 791-797. 10.1002/mds.21325. quiz 907
[18] Benes H, Kohnen R: Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med. 2009, 10 (5): 515-523. 10.1016/j.sleep.2008.06.006.
[19] Ondo W, Jankovic J: Restless legs syndrome: clinicoethiologic correlates. Neurology. 1996, 47 (6): 1435-1441.
[20] Allen RP, Earley CJ: Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med. 2000, 1 (1): 11-19. 10.1016/S1389-9457(99)00012-X.
[21] Lee KA, Zaffke ME, Baratte-Beebe K: Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. J Womens Health Gend Based Med. 2001, 10 (4): 335-341. 10.1089/152460901750269652.
[22] Manconi M, Rozea T, Katharina S, Berger K, Allen R, Trenkwalder C: Restless legs syndrome in pregnancy. Neurology. 2004, 63 (6): 1065-1069. 10.1212/01.wnl.0000140896.78668.1a.
[23] Molnar MZ, Novak M, Ambrus C, Szeifert L, Kovacs A, Pap J, Remport A, Mucsi I: Restless Legs Syndrome in patients after renal transplantation. Am J Kidney Dis. 2005, 45 (2): 388-396. 10.1053/j.ajkd.2004.10.007.
[24] Trenkwalder C, Benes H, Poewe W, Oertel WH, Garcia-Borreguero D, de Weerd AW, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, et al: Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008, 7 (7): 595-604. 10.1016/S1474-4422(08)70112-1.
[25] Winkelman JW: Considering the causes of RLS. Eur J Neurol. 2006, 13 (Suppl 3): 8-14.
[26] Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C: Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008, 23 (16): 2267-2302. 10.1002/mds.22254.
[27] Garcia-Borreguero D, Larrosa O, Albares J, Pascual M, Fernandez C, Palacio C: Pregabalin in restless legs syndrome: A double-blind, placebo-controlled study with clinical and polysomnographic assessment. Neurology. 2009, Suppl:.
[28] Kushida CA, Walters AS, Becker P, Thein SG, Perkins AT, Roth T, Canafax D, Barrett RW: A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009, 32 (2): 159-168.
[29] Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, Koester J, Reess J: Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep medicine. 2008, 9 (5): 537-541. 10.1016/j.sleep.2007.12.004.
[30] Garcia-Borreguero D, Allen RP, Benes H, Earley C, Happe S, Hogl B, Kohnen R, Paulus W, Rye D, Winkelmann J: Augmentation as a treatment complication of restless legs syndrome: Concept and management. Mov Disord. 2007, 22 (S18): S476-S484. 10.1002/mds.21610.
